Does Rallies show Form 4 insider transactions for RPRX?

Yes. Rallies tracks RPRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RPRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RPRX. It does not provide personalized investment advice.

RPRX (Royalty Pharma plc Class A Ordinary Shares) Stock Analysis - Insider Trades

Royalty Pharma plc Class A Ordinary Shares (RPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, RPRX trades at $53.06 with a market cap of $23.08B and a P/E ratio of 27.85. RPRX moved +1.21% today. Year to date, RPRX is +33.82%; over the trailing twelve months it is +60.35%. Its 52-week range spans $24.05 to $53.47. Analyst consensus is strong buy with an average price target of $59.43. Rallies surfaces RPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RPRX stock inside the company?

Recent RPRX insider activity includes Urist Marshall sold 13.68K, Norden Gregory sold 3.04K, Coyne Terrance P. sold 32.92K, Coyne Terrance P. sold 1.88K, and Coyne Terrance P. sold 1.88K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RPRX Key Metrics

Key financial metrics for RPRX
Metric	Value
Price	$53.06
Market Cap	$23.08B
P/E Ratio	27.85
EPS	$1.91
Dividend Yield	0.23%
52-Week High	$53.47
52-Week Low	$24.05
Volume	4.70K
Avg Volume	0
Revenue (TTM)	$2.44B
Net Income	$1.36B
Gross Margin	0.00%

Recent RPRX Insider Trades

Urist Marshall sold 13.68K (~$726.14K) on May 14, 2026.
Norden Gregory sold 3.04K (~$161.38K) on May 14, 2026.
Coyne Terrance P. sold 32.92K (~$1.64M) on Apr 28, 2026.
Coyne Terrance P. sold 1.88K (~$93.33K) on Apr 28, 2026.
Coyne Terrance P. sold 1.88K (~$90.62K) on Apr 1, 2026.

Latest RPRX News

Royalty Pharma Reports 13% Royalty Growth and $295M Q1 Profit — May 6, 2026
Royalty Pharma jumps as board declares $0.235 Q2 2026 dividend — Apr 19, 2026
Royalty Pharma jumps as daraxonrasib Phase 3 win triggers $250 million tranche — Apr 18, 2026
Royalty Pharma jumps as partnered Phase 3 milestone boosts expectations into Q1 report — Apr 17, 2026
Royalty Pharma jumps as recent royalty-deal flow reinforces 2026 cash-receipts outlook — Mar 31, 2026

RPRX Analyst Consensus

7 analysts cover RPRX: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $59.43.

Common questions about RPRX

Who is trading RPRX stock inside the company?: Recent RPRX insider activity includes Urist Marshall sold 13.68K, Norden Gregory sold 3.04K, Coyne Terrance P. sold 32.92K, Coyne Terrance P. sold 1.88K, and Coyne Terrance P. sold 1.88K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RPRX?: Yes. Rallies tracks RPRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RPRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RPRX. It does not provide personalized investment advice.